Several studies have reported that FXR agonists, such as 6-ethylchenodeoxycholic acid (OCA), play an anti-inflammatory and antifibrotic role in lung tissues, and FXR can be used as a new target for the treatment of certain lung diseases [13, 48]. This evidence concerns the gene NR1H4 and lung disorder.